Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study
Journal of Clinical Oncology · 10.08.2026 · 44 (23) · 2253-2254
DOI: 10.1200/jco-26-00227 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.08.2026. Verfasst von Antonio Avallone und 2 weiteren Autor:innen. Beteiligte Einrichtung: Antonio Avallone, MD, and Alfonso De Stefano, MD, PhD, Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. P…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Antonio Avallone, MD, and Alfonso De Stefano, MD, PhD, Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy; and Davide Ciardiello, MD, PhD, Division of Gas…
ORCID-Profile: Antonio Avallone, Alfonso De Stefano
Zitieren
APA
Avallone, A., De Stefano, A., & Ciardiello, D. (2026). Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study. Journal of Clinical Oncology, 44(23), 2253-2254. https://doi.org/10.1200/jco-26-00227
Vancouver
Avallone A, De Stefano A, Ciardiello D. Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study. Journal of Clinical Oncology. 2026;44(23):2253-2254. doi:10.1200/jco-26-00227
BibTeX
@article{Avallone2026,
author = {Avallone, Antonio and De Stefano, Alfonso and Ciardiello, Davide},
title = {Understanding the Contribution of Anti-EGFR Reinduction to Overall Survival in the TRIPLETE Study},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {23},
pages = {2253--2254},
doi = {10.1200/jco-26-00227}
}
EUVIMED